Astellas Pharma Europe Limited

Research activity is centred on solid organ transplant rejection, with particular attention to liver, kidney, heart, lung, and intestinal transplantation. The clinical focus includes maintenance of graft function and prevention of immune-mediated rejection in allograft recipients.

• Primary organ transplant rejection prophylaxis
• Allograft maintenance
• Post-transplant immune suppression

The sponsor’s work in this area is closely aligned with long-term care for patients requiring ongoing immunosuppressive therapy after transplantation.